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Physician Fee Schedule and represented in 2013 US dollars. Average wholesale prices 
for a 30-day supply of AA and ENZA were $7,674 and $8,940, respectively. One-way 
sensitivity analyses were performed against all probability, utility, and cost values 
incorporated into this cost-effectiveness model. Results: In this analysis, AA pro-
vides substantial saving with $13,322 per patient versus ENZA. The main drivers 
of the model are drug costs, health utility values, and efficacy (OS and rPFS). The 
robustness of the results was supported by sensitivity analyses. ConClusions: 
Given similar OS benefits, AA is cost saving compared with ENZA for the treatment 
of patients with mCPRC post-docetaxel based on US data.
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objeCtives: Pharmacoeconomic evaluations are more critical in developing 
countries in which economic effects of new and expensive therapies have sig-
nificant impact on patients, insurance companies and the health systems. Since 
cost-effectiveness studies are too costly and time consuming, in these countries 
new medications are often being used in daily practice before being well docu-
mented as cost-effective interventions. This would force health organizations 
to perform comparative studies as alternatives to cost-effectiveness analysis. 
Trastuzumab, an anti-cancer monoclonal antibody which was approved by FDA 
in 1998, is an expensive medicine introduced to the Iranian pharmaceutical market 
since 2003, with an annual usage cost of 308,352,730,640 Rials ($ US 25,000,000) in 
2010. Methods: A systematic review on electronic medical databases including 
the Cochrane, CRD, EMBASE, HEED, MEDLINE, and PubMed, covering the years 2000 
to 2009, was performed using relevant key words to extract publications investi-
gating cost-effectiveness and efficacy of trastuzumab in breast cancer treatment. 
The Incremental Cost-Effectiveness Ratios (ICERs) were compared with a criterion 
introduced by WHO. Results: The reported ICERs were between $90,118/QALY 
to $217,264/QALY and $13,361/QALY to $65,250/QALY in metastatic and adjuvant 
breast cancer therapy, respectively. The metastatic ICERs were 8 to 20 folds of the 
GDP per Capita in Iran whereas the adjuvant phase ICERs were 1.2 to 6 folds of it. 
Sensitivity analysis showed the results are more sensitive to discount rate, drug 
regimen cost, duration of survival benefits, as well as the risk of relapse and metas-
tasis. ConClusions: Trastuzumab therapy in metastatic breast cancer cannot be 
cost effective in Iran, however as adjuvant therapy it is still a challenging issue. 
Unlimited access to this medicine would not be rational and recommendations 
with an approach to optimize its usage, e.g. administration in younger patients 
with poor prognosis and higher risk of relapse or using clean rooms to reduce drug 
wasting, are strongly advised.
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the CoSt-effeCtiveNeSS of beNdamuStiNe-rituximab verSuS 
fludarabiNe-rituximab for PatieNtS with iNdoleNt NoN-hodgkiN’S 
lymPhoma (iNhl) who have ProgreSSed followiNg treatmeNt with 
rituximab or a rituximab-CoNtaiNiNg regimeN iN mexiCo
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objeCtives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Mexico. Methods: An economic model was constructed from the Mexican public 
payer perspective, with a 35-year (lifetime) horizon and a discount rate of 5%. The 
model included three health states, progression-free (PF), progressive disease (PD), 
and death, which were associated with utility weights of 0.81, 0.62 and 0, respec-
tively. Clinical inputs (response rates, Kaplan-Meier curves, hazard ratios (HRs) and 
adverse event rates) were from the Stil NHL 2-2003 study. Resource use data were 
from interviews with Mexican hematologists treating iNHL patients. Unit costs were 
obtained from Mexican Social Security Institute (IMSS) and were expressed as 2013 
Mexican Pesos. Univariate and probabilistic sensitivity analyses were conducted to 
determine the key drivers of cost-effectiveness, and uncertainty around the results, 
respectively. Results: Total cost of Ben-R was $1,726,828 and total cost of Fdb-R 
was $1,640,024. Ben-R patients accrued more LYs (5.82 vs. 4.73), QALYs (4.22 vs. 3.29), 
and PF LYs (3.37 vs. 1.96) compared to Fdb-R patients. The ICERs were $79,890 (cost 
per LY), $92,788 (cost per QALY) and $61,486 (cost per PF LY). Univariate sensitivity 
analysis revealed that the ICER per LY was most sensitive to the PF survival (PFS) and 
overall survival (OS) HRs for Ben-R vs Fdb-R and the use of bone marrow transplants 
in the PD state. Probabilistic sensitivity analysis with 1,000 iterations estimated that 
Ben-R will be cost effective over 90% of the time at a willingness-to-pay threshold 
of $125,085. ConClusions: At a willingness-to-pay of $125,085 (GDP per capita of 
Mexico) Ben-R is cost effective versus Fdb-R.
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objeCtives: In Romania the estimated incidence of metastatic renal cancer 
(mRCC) is about 1500 cases; less than 400 patients receive full reimbursement for 
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objeCtives: To provide an overview on published decision-analytic models 
evaluating treatment strategies for multiple myeloma (MM) focusing on the cost-
effectiveness results. Methods: A systematic literature search was performed in 
the electronic databases Pubmed, NHS EED and the Tufts CEA Registry to identify 
studies evaluating MM treatment strategies using mathematical decision-analytic 
models. To meet the inclusion criteria, models were required to compare different 
treatment strategies, to be published as full text articles in English, and com-
prise relevant clinical health outcomes over a defined time horizon and popula-
tion. We used evidence tables to summarize methodological characteristics and 
economic results. For comparability, all economic results were transferred into 
2012 US Dollar. We used Purchasing Power Parity to convert the currency into US 
Dollar of the same year. For converting US Dollar from step one into US Dollars 
2012, we used Consumer Price Index rates for the relevant year. Results: We 
found eleven decision-analytic modeling studies. Economic evaluations were 
included in all studies. Eight studies reported cost-utility results. The modeling 
approaches applied included a decision tree model, Markov cohort model, discrete 
event simulations, partitioned survival analyses and area under the curve models. 
Time horizons ranged from seven years to lifetime. Half of the models chose the 
perspective of the health care system, while other perspectives were societal, 
third party payer and government payer. Among others, two studies reported cost-
effectiveness of autologous transplantation vs. standard-dose melphalan with an 
ICER of $31,263 /life-year gained (LYG) and $36,778/LYG. One study reported that 
bortezomib vs. lenalidomide plus dexamethasone is cost saving, while another 
comparable study reported an ICUR for lenalidomide plus dexamethasone vs. 
bortezomib of $22,301/QALY. ConClusions: We identified several well-designed 
cost-effectiveness/cost-utility models using a broad variety of different modeling 
approaches. Results of most of the studies were not comparable due to different 
treatment strategies, target population and settings.
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objeCtives: To examine the empirical and methodological cost-effectiveness evi-
dence of surgical interventions for breast, colorectal, and prostate cancer. Methods: 
Systematic searches of seven databases including MEDLINE, EMBASE, CDSR,HTA, 
DARE, EconLit and NHSEED, research registers, the National Institute of Health and 
Care Excellence (NICE) website and conference proceedings was conducted in April 
2012. Studies were included if they evaluated the cost-effectiveness of a surgical 
procedure in either breast, colorectal or prostate cancer and reported cost per quality 
adjusted life-year or cost per life-year results. The quality of the studies included was 
assessed in terms of meeting essential, preferred, and UK specific requirements for 
economic evaluations. Results: The 17 (breast= 3,colorectal= 7,prostate= 7) studies 
which satisfied the inclusion criteria covered a broad range of settings with 9 set in 
European and 8 in non-European locations. Just a third (11/17) was published within 
the last 10 years. In terms of the essential quality criteria; the populations, inter-
ventions and comparators were generally well defined. However, very few studies 
were informed by the results of literature reviews or synthesised clinical evidence. 
Although the interventions had potential differential effects on recurrence and mor-
tality rates, some studies used relatively short time horizons. Although univariate 
sensitivity analyses were reported in all studies, less than a third characterised all 
uncertainty with a probabilistic sensitivity analysis. While a third of studies incorpo-
rated patients’ health-related quality of life data, only 4 of the 17 studies used social 
tariff values. ConClusions: There is very little recent robust evidence describing 
the cost-effectiveness of surgical interventions in these indications. Many of the 
more recent publications did not satisfy the essential methods requirements, such 
as using synthesising clinical evidence informed by a systematic literature review. 
Given the ratio of potential benefit and harm associated with surgery in cancer, there 
is an urgent need to conduct additional robust economic evaluations in this area.
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objeCtives: With approvals of abiraterone acetate (AA) and enzalutamide (ENZA) 
in the past 2 years, the treatment landscape has shifted dramatically for metastatic 
castration-resistant prostate cancer (mCRPC) patients who failed docetaxel-based 
chemotherapy. There is increasing interest in the relative cost-effectiveness of these 
therapies. The objective of this study was to assess the cost-effectiveness of AA 
versus ENZA among individuals with mCRPC post chemotherapy from a payer per-
spective. Methods: A survival-based Markov cohort model consisting of 3 health 
states, progression-free, progressed, and dead, was developed to project over 10 
year period. Progression between states was determined by overall survival (OS) 
and radiographic progression free survival (rPFS). An indirect treatment comparison 
was conducted to determine the relative efficacy of AA and ENZA (data reported 
separately). Utilities were mapped from FACT-P to EQ-5D based on a review of the 
literature. Drug acquisition costs in the US were used since ENZA was approved only 
in the US at the time of analysis. Costs of scheduled and unscheduled follow-up 
visits were obtained from the Centers for Medicare Services Drug Payment Table and 
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is associated with decreased quality of life, and poorer health outcomes. Therefore, 
there may be considerable gains in the adequate treatment of depression in oncol-
ogy patients. We explored the cost-effectiveness of a collaborative care intervention 
specifically developed for the treatment of depression in cancer patients compared 
to usual practice. Methods: A cost-effectiveness analysis comparing a collaborative 
care intervention for depression management, Depression Care for People with Cancer 
(DCPC), in addition to usual care with usual care alone, based on data from the second 
Symptom Management Research Trials in Oncology (SMaRT-2). SMaRT-2 was a large 
(n= 500), multicentre study, in depressed patients with a relatively good cancer progno-
sis, in a secondary care setting. Outcomes included costs expressed as UK sterling in 
2010-11 prices and health outcomes in quality-adjusted life-years (QALYs), estimated 
from a National Health Service and Personal Social Services perspective. Scenario 
analyses were performed to determine the impact on cost-effectiveness of alternative 
costing assumptions, and uncertainty was characterised through cost-effectiveness 
acceptability curves and probabilities of cost-effectiveness at key cost-effectiveness 
thresholds. Results: DCPC in addition to usual care was associated with greater costs, 
but also improved health outcomes. DCPC was found to be cost-effective at accepted 
cost-effectiveness thresholds. Results were robust across alternative scenarios, with 
probabilities of cost-effectiveness higher than 90% for cost-effectiveness thresholds 
ranging between £20,000-30,000 per QALY. ConClusions: Compared to usual care, 
DCPC in addition to usual care is likely to be cost-effective at current UK cost-effec-
tiveness thresholds. This contributes to the growing evidence on the cost-effectiveness 
of collaborative care interventions for the treatment of comorbid depression. Future 
research will use a decision modelling approach to extrapolate trial-based results 
across a longer time horizon, and incorporate other relevant sources of evidence.
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objeCtives: The purpose of this study was to explore the cost-effectiveness 
of abiraterone acetate (abiraterone) vs. cabazitaxel in metastatic castration-
resistant prostate cancer (mCRPC) patients who progressed after docetaxel in 
Kazakhstan. Methods: Since no head-to-head trial data were not available for 
Abiraterone against cabazitaxel, indirect profitability model was developed using 
clinical data (progression-free survival (PFS), overall survival (OS), adverse events 
(AEs)) from the pivotal Phase 3 clinical trials COU-AA-301 (Abiraterone) and TROPIC 
(cabazitaxel). The basic assumption in the model was that the two comparator arms 
in the trials were “palliative” and are therefore equivalent. Using the resources, 
in particular for controlling the adverse events was calculated based on data 
Kazakhstan. For validation purposes, a secondary analysis was conducted using 
international resources use data. The analysis used a local expenditures 2011-2012, 
undiscounted. Hospitalization, day hospital visits, medications, and laboratory tWe 
developed a Markov microsimulation model with a lifetime horizon and a direct 
health-care cost perspective. The patient history was recorded and was used in 
calculations of transition probabilities, utilities, and costs. ests were taken from 
the public officially published rates. The cost of purchasing drugs came from recent 
price lists . Calculations were based on the average duration of treatment for each 
agent. Results: The total cost of treatment was lower for Abiraterone compared 
with cabazitaxel. Higher costs for the purchase of medicines for Abiraterone were 
offset by lower administrative expenses and lower AE management costs. Results 
were confirmed by secondary analysis. All sensitivity analyzes from the point of 
view of the model parameters and modeling assumptions are consistent with the 
expected findings, which confirmed both internal and external consistency of the 
model. ConClusions: Abiraterone is a potentially cost-effective option compared 
with cabazitaxel in the health care system in Kazakhstan.
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objeCtives: The aim of this study was to evaluate duration and cost of prophylactic 
use of antibiotics, as well as occurrence of postoperative infection in the patients (pts) 
with laryngeal and pharyngolaryngeal carcinoma during 2005 and 2010. Methods: 
Histories from 87 pts (2005) and 92 pts (2010) who were treated during the year 2005 
and 2010 from laryngeal and pharyngolaryngeal carcinoma at the ENT Clinic, Clinical 
Center of Vojvodina, Novi Sad, Serbia, have been used. All pts received triple drug 
therapy perioperatively. Since 2009, additional hygienic measures and education of 
staff (in terms of the proper use of antibiotics) have been taken to improve hospi-
tal treatment. From the patients’ histories, we followed: average length of hospital 
stay,average length of administrating antibiotics, occurrence of infection or other 
postoperative complication (fistula) and the price of used antibiotics. Results: 
During 2005, antibiotics were administrated as follows: aminoglycosides (amikacin) 
2x500mg during 10 days, cephalosporin (cefazolin amp. 2x1g, cefrtriakson 2x1g) 10 
days, metronidazole (solutio) 3x500mg 10 days.During 2010, same anibiotics were 
administerd for an average of 3 days. The average length of hospital stay was in 2005. 
was 13.5 days, x+/- SD= 13.5+/-4.2, and in 2010 was 11.18 days, x+/- SD= 11.18+/-5.9. The 
average length of administrating antibiotics was 9.4 days in 2005 (x+/- SD= 9.4+/-1.1) 
and in 2010 was 3.4 days (x+/- SD= 3.4+/-1.7). Occurrence of infection was in 4 pts (2005) 
and 6 pts (2010). The cost of used antibiotics in 2005.was 775748 dinars (9320 euros), 
and in 2010. was 366159 dinars (3698euro). ConClusions: With reducing the length 
of administrating same antibiotics, after additional hygienic and educative measures 
have been taken, it is possible to significantly reduce the length of hospital stay (while 
the number of postoperative infections is not significantly increased) and cost of used 
antibiotics, which altogether leads to reduction of overall cost of hospital treatment.
their therapy. Our objective was to assess the cost-effectiveness of Sunitinib (SU) in 
the first-line treatment of mRCC patients in comparison with Bevacizumab (BEV) 
+ IFN- and Sorafenib (SO) -at the level of 2011 year- based on the latest clinical evi-
dence. Methods: A Markov model (comprised of four states: 1st line treatment, 
2nd line, Best Supportive Care and Death) was validated in several countries and 
was adapted for the Romanian jurisdiction. The model was set to 6 weekly cycles 
for a period of 10 years, which corresponds with a lifetime length scenario. Costs 
for medication and application were derived from hospital databases, expert panels 
and structured interviews. Experts that managed more than 60% of all local mRCC 
were consulted. These experts identified several scenarios related to outpatient and 
inpatient treatment decisions predominantly based on social reasons; all these sce-
narios have been tested. A WHO methodology was used to set a threshold of price per 
QALY (3 x local GDP) Results: Cost per cycle in 1st line was lower than both 2nd line 
and BSC – consistent with other international findings. Neutropenia, proteinuria and 
heart failure have been identified as the most costly adverse events. The QALYs for 
SU was 1.86 compared to BEV 1.7 and SO 1.69. Incremental cost per QALY SU versus 
SO was 14.000 EURO and, respectively, -141.000 EURO versus BEV. ConClusions: 
Sutent is cost effective versus SO and dominant to BEV in the treatment of mRCC in 
the study settings. The model was very sensible to price of medication and cost of BSC.
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objeCtives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
direct cell death compared with rituximab, and is pending regulatory approval (in 
combination with chlorambucil (Clb)) for the treatment of patients with previously 
untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has shown 
a > 85% reduction in the risk of progression, relapse or death in comparison to 
treatment with Clb alone (HR 0.14, 95% CI 0.09-0.21, p < .0001), a broadly accepted 
treatment option for many patients with co-existing medical conditions. The 
cost-effectiveness of this innovative therapy will need to be assessed in countries 
using incremental cost-effectiveness thresholds to make reimbursement deci-
sions. Methods: A four-state Markov lifetime model from the UK NHS perspective 
was developed for patients with existing medical conditions utilizing the patient-
level information from the underlying clinical trial comparing obinutuzumab+Clb 
versus rituximab+Clb and versus Clb alone (CLL11 trial). Transition probabilities 
from PFS to progression were derived from this study’s data. Post-progression sur-
vival was estimated using published data and was part of the sensitivity analy-
ses. Cost data (e.g. administration and adverse events), utilities and the prices for 
rituximab and Clb were retrieved for the UK. As obinutuzumab is not yet approved 
a range of price assumptions of similar innovative oncology therapies has been 
applied. Results: Based on this early evaluation, obinutuzumab+Clb showed a cost 
per QALY in the base case analysis of £18,000 to £19,000 when compared to Clb and 
£29,000 to £32,000 when compared to rituximab+Clb. Probabilistic and deterministic 
sensitivity analyses confirmed these findings. ConClusions: Obinutuzumab+Clb 
showed significant patient-relevant clinical benefits and might be a potential cost-
effective therapy in comparison to the current standard of care and could hence 
support access for a maximum number of patients with previously untreated CLL.
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objeCtives: National programmes of breast cancer screening are common for women 
over the age of 50 at average risk. For women aged less than 50, surveillance may be 
offered to those at elevated risk either due to family history or because of identified 
genetic risk factors, such as a BRCA1 mutation. The lifetime risk for these women is not 
known with certainty. The purpose of this study was to examine the cost-effectiveness 
of different screening strategies as a function of lifetime risk. Methods: A Markov 
model was developed to evaluate the cost-effectiveness of different MRI- and digital 
mammography-based surveillance strategies between the ages of 30 and 49. Costs 
and benefits were calculated to life expectancy. The perspective was that of the pub-
licly funded health care system in Ireland. Lifetime risk of developing breast cancer 
was varied between 4% and 94%. A cost-effectiveness threshold of € 45,000/QALY was 
applied. Results: The probability of cost-effectiveness increased with increasing 
lifetime risk. For women at moderate risk (i.e. lifetime risk of between 17% and 30%), 
cost-effectiveness was only achieved with annual surveillance from the age of 40 to 
49 when lifetime risk reached 28% to 30%. For women with high familial risk, cost-
effectiveness was achieved for surveillance from the age of 40 to 49. For women with 
a BRCA1 mutation, surveillance from the age of 40 to 49 was cost-effective for all levels 
of lifetime risk, while MRI from age 30 was only cost-effective for a lifetime risk of over 
65%. ConClusions: Risk levels for breast cancer encompass wide ranges of lifetime 
risk. The cost-effectiveness of different surveillance strategies is sensitive to lifetime 
risk and suggests the need for individualised surveillance programmes.
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objeCtives: Collaborative care interventions for comorbid depression have dem-
onstrated their beneficial impact on health outcomes. Depression in cancer patients 
